RCM
SABSW icon

Rivernorth Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Rivernorth Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46,665
Closed -$84K – 842
2021
Q4 		$84K Sell
46,665
-3,333
-7% -$6.12K ﹤0.01% 507
2021
Q3 		$45K Hold
49,998
– – ﹤0.01% 462
2021
Q2 		$46K Hold
49,998
– – ﹤0.01% 441
2021
Q1 		$30K Buy
+49,998
New +$51.9K ﹤0.01% 427

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rivernorth Capital Management's SABSW Position: Q1 2022 in Review

Rivernorth Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2022, closing a stake of 46,665 shares — an estimated $84K sold.

Rivernorth Capital Management first reported a position in SABSW in Q1 2021 and held it in 4 quarters. The position peaked at $84K in Q4 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q1 2022.

  • Rivernorth Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q1 2022 after selling out during the quarter.
  • Rivernorth Capital Management sold 46,665 SAB Biotherapeutics Warrant shares in Q1 2022, an estimated $84K.
  • Rivernorth Capital Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 4 quarters.
  • Rivernorth Capital Management's SAB Biotherapeutics Warrant position peaked at $84K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2022.

Based on Rivernorth Capital Management's 13F filing for Q1 2022, filed 16 May 2022.